Published: Sat, April 08, 2017
Economy | By Melissa Porter

Comerica Bank Has $1826000 Stake in Akorn, Inc. (AKRX)

Comerica Bank Has $1826000 Stake in Akorn, Inc. (AKRX)

Akorn, Inc. (NASDAQ:AKRX)'s stock had its "buy" rating reiterated by investment analysts at Jefferies Group LLC in a note issued to investors on Wednesday.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. The company presently has a consensus rating of "Hold" and an average target price of $28.83.

Several other analysts have also recently weighed in on the stock. Alpha One also assigned news headlines about Akorn an impact score of 95 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. P/E Ratio is for valuing a company that measures its current share price relative to its per-share earnings. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. WallachBeth Capital raised their price target on Akorn from $22.00 to $25.00 and gave the company a "hold" rating in a research report on Friday, March 10th. The stock boasts a consensus analyst "Buy" rating with the consensus recommendation standing at 2.00.

In September, the company made its biggest deal ever with the acquisition of Spain's private hospital chain Quironsalud for 5.8 billion euros ($6.14 billion), including assumed debt. The firm has a 50-day moving average price of $22.70 and a 200-day moving average price of $22.81.

Akorn (NASDAQ:AKRX) last issued its quarterly earnings results on Wednesday, March 1st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.57 by $0.01. The Return on Equity (ROE) value stands at -57.7%. The firm's revenue was up 1.3% compared to the same quarter previous year. Analysts anticipate that Akorn will post $1.63 earnings per share for the current fiscal year.

The share of Akorn, Inc. Envestnet Asset Management Inc. now owns 29,265 shares of the company's stock worth $637,000 after buying an additional 320 shares in the last quarter. While looking the figure depicted by the Price to Earning we can suggest that the shares of Akorn, Inc. Its monthly volatility value of 3.68% and volatility for the week is valued at 4.92%. LS Investment Advisors LLC boosted its position in shares of Akorn by 11.6% in the third quarter. Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally.

Like this: